Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Advances Antibody R&D Agenda With Agensys Purchase Worth Up To $537 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

Privately held Agensys brings a proprietary portfolio of cancer targets, a preclinical pipeline of mAbs and small proteins, and antibody manufacturing capabilities.

You may also be interested in...



Astellas Wins OSI But Victory Comes At A Price

Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17 with a definitive merger agreement that has the unanimous support of both companies' boards

Astellas Wins OSI But Victory Comes At A Price

Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17 with a definitive merger agreement that has the unanimous support of both companies' boards

Astellas Wins OSI But Victory Comes At A Price

After months of drama, Astellas ups its bid to $4 billion cash to seal its hostile-turned-friendly bid for Tarceva maker OSI.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel